期刊
NEUROLOGICAL RESEARCH
卷 34, 期 7, 页码 669-676出版社
TAYLOR & FRANCIS LTD
DOI: 10.1179/1743132812Y.0000000063
关键词
2D-DIGE; Cerebrospinal fluid; Parkinson's disease; Proteomics
资金
- Chelsea Therapeutics
- Teva Neuroscience
- Schering-Plough
- Kalaco Scientific
- Avid Radiopharmaceuticals
- Avid
- Bayer
- Baxter
- BMS
- Lilly
- GE
- Janssen
- Celegene
- Pfizer
- Arizona Parkinson's Disease Consortium [1001]
- Brain Donation Program at Banner Sun Health Research Institute
- National Institute on Aging [P30 AG19610]
- Arizona Department of Health Services [211002]
- Arizona Biomedical Research Commission [4001, 0011, 05-901]
- Michael J. Fox Foundation for Parkinson's Research
Objectives: Parkinson's disease (PD) afflicts approximately 1-2% of the population over 50 years of age. No cures or effective modifying treatments exist and clinical diagnosis is currently confounded by a lack of definitive biomarkers. We sought to discover potential biomarkers in the cerebrospinal fluid (CSF) of neuropathologically confirmed PD cases. Methods: We compared postmortem ventricular CSF (V-CSF) from PD and normal control (NC) subjects using two-dimensional difference gel electrophoresis (2D-DIGE). Spots exhibiting a 1.5-fold or greater difference in volume between PD patients and controls were excised from the two-dimensional gels, subjected to tryptic digestion and identification of peptides assigned using mass spectrometric/data bank correlation methods. Results: Employing this strategy six molecules: fibrinogen, transthyretin, apolipoprotein E, clusterin, apolipoprotein A-1, and glutathione-S-transferase-Pi, were found to be different between PD and NC populations. Discussion: These molecules have been implicated in PD pathogenesis. Combining biomarker data from multiple laboratories may create a consensus panel of proteins that may serve as a diagnostic tool for this neurodegenerative disorder.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据